Avails Medical is a pioneer in rapid, automated, all-electrical antibiotic susceptibility testing (AST). Founded by a team of Stanford post-docs, Avails’ electronic biosensor technology is designed to improve speed and accuracy in pathogen quantification and susceptibility testing directly from human specimens by eliminating crude, time-consuming culturing steps. Avails eQUANT technology enables a single-step automated 0.5 McFarland preparation (in as fast as 40 minutes) directly from positive blood culture (PBC), removing 18+ hours from workflow by eliminating the need for subcultures. eQUANT enables legacy AST systems to be used directly from PBC, extending their useful life by 10 – 15 years. eQUANT also allows for direct-from-PBC disk diffusion. Avails is developing a rapid phenotypic AST (eAST) for use directly from PBC as well as cultured isolates with 90% faster results for antibiotic therapy. eAST will be a critical step forward in improving accurate and efficient antibiotic therapy decisions in multi-drug resistant infections. Avails' electrical biosensor platform fits within a lab's existing workflow and budget. Its modular development enables maximum flexibility from single-slot systems to any number of multi-slot systems, serving all market segments from smaller community hospitals to larger academic labs.